76 results about "Phospholipase A" patented technology

This invention provides methods for the use of substituted indole compounds of the general formula:

and pharmaceutically acceptable salt forms thereof. The invention provides methods for the use of the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A₂ enzymes, and for the medical treatment, prevention and inhibition diseases and disorders including asthma, stroke, atherosclerosis, multiple sclerosis, Parkinson's disease, arthritic disorders, rheumatic disorders, central nervous system damage resulting from stroke, central nervous system damage resulting from ischemia, central nervous system damage resulting from trauma, inflammation caused or potentiated by prostaglandins, inflammation caused or potentiated by leukotrienes, inflammation caused or potentiated by platelet activation factor, pain caused or potentiated by prostaglandins, pain caused or potentiated by leukotrienes, and pain caused or potentiated by platelet activation factor.

The invention provides novel polypeptides having phospholipase activity, including, e.g., phospholipase A, B, C and D activity, patatin activity, phosphatidic acid phosphatases (PAP) and/or lipid acyl hydrolase (LAH) activity, nucleic acids encoding them and antibodies that bind to them. Industrial methods, e.g., oil degumming, and products comprising use of these phospholipases are also provided.

This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A₂ enzymes (cPLA₂), more particularly including inhibitors of cytosolic phospholipase A₂ alpha enzymes (cPLA₂α). In some embodiments, the inhibitors have the Formula I:

wherein the constituent variables are as defined herein.

Modified oligonucleotides having a conserved G₄ sequence and a sufficient number of flanking nucleotides to significantly inhibit the activity of a virus or phospholipase A₂ or to modulate the telomere length of a chromosome are provided. G₄ quartet oligonucleotide structures are also provided. Methods of prophylaxis, diagnostics and therapeutics for viral-associated diseases and diseases associated with elevated levels of phospholipase A₂ are also provided. Methods of modulating telomere length of a chromosome are also provided; modulation of telomere length is believed to play a role in the aging process of a cell and in control of malignant cell growth.

This invention provides methods for treating in mammals arthritic or rheumatic disorders using substituted indole compounds of the general formula:

and pharmaceutically acceptable salt forms thereof, and methods for using the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A₂ enzymes, and for the medical treatment, prevention and inhibition of pain and inflammation.

Disclosed is a method for preparing L-α-Glycerylphosphorylcholine with high yields and purity. The method uses phospholipase A₁-based enzymatic hydrolysis, ion-exchange resin purification and silica gel column chromatography to prepare L-α-glycerylphosphorylcholin with purity up to 99.8% and a final yield up to 78.4%. The method disclosed is simple, cost-effective, environmentally friendly, and adaptable to industrial applications.

The present invention provides methods of preventing and treating neural inflammatory or demyelinating disease, such as multiple sclerosis, via an inhibition of the activity or expression of phospholipase A₂. The invention further relates to methods of identifying phospholipase A₂ inhibitors and their use thereof for the prevention and/or treatment of neural inflammatory or demyelinating disease. An observed increase in the amount of phospholipase A₂ in neural lesions in the EAE animal model system indicates that elevated phospholipase A₂ activity or levels correlate with neural inflammatory or demyelinating disease. Therefore, in a further aspect the invention provides methods for the diagnosis and prognostication of neural inflammatory or demyelinating disease, such as multiple sclerosis.

This invention open a cold tolerance of Serratia sand Habitat-chuen (Serratia fonticola) xjF1 CGMCC No.1971, through the strain characteristics, enzyme production conditions and the nature of enzyme research, proved a new phospholipase A1 gene consists of two open plA and plS reading frame, was certified plA gene coding phospholipase A1, plS gene coding phospholipase A1 auxiliary protein. This invention relates to the gene containing the recombinant plasmid and reorganization cell, the gene expression products phospholipase A1 in the show activity under low-temperature conditions, can be used in industries such as oil refining process can be simplified production process, lowering energy consumption, improve product quality , protecting the environment, reduce production costs, have important practical significance.

The invention relates to a method for preparing magnetic immobilized phospholipase A1 and a method for refining crude oil by using the magnetic immobilized phospholipase A1. The invention aims to solve the problems of complicated separation and recycling of immobilized enzyme and low activity recovery of the conventional method for preparing the immobilized phospholipase A1, and the problem that the magnetic immobilized enzyme is not used for refining the crude oil at present. The method for preparing and refining the crude oil comprises the following steps of: 1, preparing the magnetic immobilized phospholipase A1; 2, heating the crude oil, and adding citric acid solution; and 3, cooling, regulating the pH value, adding the magnetic immobilized phospholipase A1, stirring, and separating the magnetic immobilized phospholipase A1. The recovery rate of the prepared magnetic immobilized phospholipase A1 is over 85 percent, and the phosphorus content of the crude oil is reduced to 7-10mg/kg. The invention is applied to the field of oil degumming.

It is intended to provide koji mold-origin phospholipase A₂ and a DNA encoding it. Namely, phospholipase A₂ comprising the following protein (a) or (b): (a) a protein having an amino acid sequence represented by SEQ ID NO: 1 or 2; and (b) a protein having an amino acid sequence derived from an amino acid sequence represented by SEQ ID NO: 1 or 2 by a partial modification and serving as phospholipase A₂.

The invention relates to a method for refining camellia seed crude oil, in particular to a method for refining the camellia seed crude oil by using immobilized phospholipase A1. The technical scheme of refining the camellia seed crude oil by using the immobilized phospholipase A1provided by the invention is realized by the following steps of: a, immobilizing phospholipase; b, carrying out pre-treatment on the camellia seed crude oil; c, adding the immobilized phospholipase into the camellia seed crude oil; and d, agitating and then centrifuging, namely realizing that the camellia seed crude oil is refined by using the immobilized phospholipase. The method for refining the camellia seed crude oil provided by the invention has the beneficial effects that unsaturated fatty acid is lost for 1-3% and is reduced by 15-20% compared with the loss of the unsaturated fatty acid in chemically-refined camellia seed oil; the immobilized phospholipase A1 is degummed to reduce phosphorus content in the oil to be lower than 5 mg/kg; the heat resistance of the immobilized phospholipase A1 is improved; the immobilized phospholipase A1 can keep a higher activity in a wider pH value range and the sensitivity of the immobilized phospholipase A1 to a reaction environment is reduced, so that the operation conditions are easier to control and implement.

The invention discloses a recombinant escherichia coli for producing phospholipase D and an application thereof, which belongs to the technical field of bioengineering. A phospholipase D gene is obtained through clone in Streptomyces ambofaciens by means of molecular biology measures, constructed expression plasmid is guided into E. coli BL21(DE3), and phosphatase-containing engineering bacteria formed by highly copying and recombining an expression carrier are obtained through kanamycin resistant plate screening. The recombinant phospholipase D is used for converting phosphatidylcholine and serine to generate phosphatidylserine, and efficient production of vitamin C-2-phosphate is achieved. By carrying out reaction for 2 h at the temperature of 40 DEG C with the pH value of 4.5, the yield of phosphatidylserine can reach 15.8 g/L, the conversion rate is 63.9%, and the space time yield is 7.9 g/L/h.

Compounds for determining the activity of phospholipase A₂, are described herein, and include embodiments having formula (1)

The invention discloses a method for enzymatic preparation of glycerophosphorylcholine. The method comprises the following steps: (1) mixing phosphatidylcholine-containing phospholipid with a hydroxyl donor, phospholipase and partial glyceride lipase, and then conducting hydrolysis or alcoholysis reaction, wherein phospholipase is one or the mixture of two of phospholipase A and phospholipase B; and (2) separating resultants and reclaiming glycerophosphorylcholine. The invention relates to the method in which phospholipase and partial glyceride lipase are together used for enzyme reaction to catalyze phosphatidylcholine in the substrate and remove acyl from fatty acid to prepare glycerophosphorylcholine. When partial glyceride lipase and phospholipase are used together, the conversion rate of phosphatidylcholine, the enzyme reaction rate and the yield of glycerophosphorylcholine are far higher than independent use of phospholipase, the conversion rate of phosphatidylcholine in the substrate can be more than 95%, and the reaction duration can be less than one hour.

The invention provides a recombinant Escherichia coli, and a method for preparing phospholipase A1 through using the recombinant Escherichia coli. A gene-recombinant Escherichia coli BL21(DE3)/pET-pla CCTCC M 2012423 with the phospholipase A1 from liquefied Serratia liquefaciens CICC No.21538 is successfully constructed in the invention, and undergoes liquid fermentation to prepare hemolytic phospholipase A1, and the preparation method of the hemolytic phospholipase A1 comprises the steps of inclined plane culture, seed culture, autonomous induction culture (comprising permeable substance addition), and crude enzyme liquid extraction. The method for preparing the phospholipase A1 through the recombinant Escherichia coli has the advantages of high enzyme yield, high enzyme activity, simple production technology, short production period, low cost, easy technological amplification and the like, and can be widely applied to the grease refining field, the phosphatide modification field and the like.

The invention provides a novel calcium-independent cytosolic phospholipase A₂/B enzyme, polynucleotides encoding such enzyme antibodies to such enzyme, and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.

This invention provides methods for treating in mammals asthma and asthmatic conditions using substituted indole compounds of the general formula:

and pharmaceutically acceptable salt forms thereof, and methods for using the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A₂ enzymes, and for the medical treatment, prevention and inhibition of pain and inflammation.